Salute e Benessere
Innocan Pharma Announces Closing of Private Placement for Gross Proceeds of C$635,444.60
Each Unit is comprised of one common share of the Company (a " ") and one common share purchase warrant of the Company (a " "). Each Warrant will entitle the holder thereof to purchase one Common Share at an exercise price of C$0.28 for a period of four (4) years from the date of issuance.
The Company paid an arm's length finder a cash fee of C$13,500 and issued to the finder 67,500 warrants attributable to investors introduced to the Company by the finder within 3 months following such introduction (" "). Each Finder Warrant entitles the Finder to purchase one Common Share at an exercise price of C$0.28 for a period of four (4) years from the date of issuance.
: "I am thrilled with this successful closing of this private placement round, which reflects strong investor confidence in Innocan's long-term vision, strategic direction as well as our proprietary CBD-loaded liposome platform technology (LPT) and our strongly growing consumer wellness operations. These new funds raised will allow us to further advance our innovative LPT through its regulatory milestones, and furthers our long-term goal of enhancing health and wellness worldwide."
The Company intends to use the proceeds from the Offering for working capital and general corporate purposes.
This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful, including any of the securities in the United States of America . The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the " ") or any state securities laws and may not be offered or sold within the United States or to, or for account or benefit of, U.S. Persons (as defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws or pursuant to an exemption from such registration requirements.
Innocan is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan carries on business through its 60% owned subsidiary, BI Sky Global Ltd. which focuses on advanced, targeted online sales.
For further information, please contact:
Iris Bincovich, CEO
+1-516-210-4025
+972-54-3012842
+44 203 769 9377
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
View original content: https://www.prnewswire.co.uk/news-releases/innocan-pharma-announces-closing-of-private-placement-for-gross-proceeds-of-c635-444-60--302340657.html